Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data
Open Access
- 13 December 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 107 (1), 366
- https://doi.org/10.1093/jnci/dju366
Abstract
The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, overdiagnosis, and costs. Based on data of the ERSPC trial, we predicted the numbers of prostate cancers diagnosed, prostate cancer deaths averted, life-years and quality-adjusted life-years (QALY) gained, and cost-effectiveness of 68 screening strategies starting at age 55 years, with a PSA threshold of 3, using microsimulation modeling. The screening strategies varied by age to stop screening and screening interval (one to 14 years or once in a lifetime screens), and therefore number of tests. Screening at short intervals of three years or less was more cost-effective than using longer intervals. Screening at ages 55 to 59 years with two-year intervals had an incremental cost-effectiveness ratio of $73000 per QALY gained and was considered optimal. With this strategy, lifetime prostate cancer mortality reduction was predicted as 13%, and 33% of the screen-detected cancers were overdiagnosed. When better quality of life for the post-treatment period could be achieved, an older age of 65 to 72 years for ending screening was obtained. Prostate cancer screening can be cost-effective when it is limited to two or three screens between ages 55 to 59 years. Screening above age 63 years is less cost-effective because of loss of QALYs because of overdiagnosis.This publication has 39 references indexed in Scilit:
- Quality-of-Life Effects of Prostate-Specific Antigen ScreeningThe New England Journal of Medicine, 2012
- Quality of Life and Guidelines for PSA ScreeningThe New England Journal of Medicine, 2012
- The impact of PLCO control arm contamination on perceived PSA screening efficacyCancer Causes & Control, 2012
- Optimization of PSA Screening PoliciesMedical Decision Making, 2011
- Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate CancerJournal of Urology, 2011
- How Does Early Detection by Screening Affect Disease Progression?Medical Decision Making, 2011
- Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerBritish Journal of Cancer, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI Journal of the National Cancer Institute, 2009
- Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized TrialJNCI Journal of the National Cancer Institute, 2008
- Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effectiveEuropean Journal of Surgical Oncology, 2007